Adhezion Biomedical announced today that it inked a long-term supply deal with Pfizer (NYSE:PFE) for exclusive U.S. distribution rights for Adhezion’s topical skin adhesives.
The Wyomissing, Pa.-based medical device company has a product family of 2-octyl cyanoacrylate adhesives designed to hold the edges of skin wounds together, for use after minimally invasive surgery and simple lacerations from trauma. They can also be used in combination with deep dermal sutures, according to Adhezion.
“It is my pleasure to announce that the Surgiseal product family of brands can now be purchased from Pfizer Inc., in the U.S. and its territories and possessions,” chairman & CEO Pete Molinaro said in prepared remarks. “Pfizer is one of the world’s premier biopharmaceutical companies, and this partnership offers strong support for our business.”
Pfizer has not released an official statement on the deal, as of this morning. Its stock closed at $34.65 apiece yesterday, up 1.61%.
